Jin Medical International (ZJYL) Liabilities and Shareholders Equity (2022 - 2025)

Jin Medical International has disclosed Liabilities and Shareholders Equity across 4 years of filings, most recently posting $53.4 million for Q3 2025.

• Liabilities and Shareholders Equity for Q3 2025 came in at $53.4 million, up 16.52% year-over-year; the trailing twelve-month figure through Sep 2025 was $99.2 million (up 26.0% YoY), and the FY2025 annual result was $53.4 million, up 16.52% from the prior year.
• Liabilities and Shareholders Equity came in at $53.4 million for Q3 2025 at Jin Medical International, up from $45.8 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $53.4 million in Q3 2025 to a low of $20.9 million in Q3 2022.
• The 4-year median for Liabilities and Shareholders Equity is $39.4 million (2023), against an average of $38.3 million.
• Across the five-year window, Liabilities and Shareholders Equity soared 57.14% in 2023 and climbed 16.52% in 2025, its largest moves.
• Jin Medical International's Liabilities and Shareholders Equity stood at $20.9 million in 2022, then jumped by 57.14% to $32.9 million in 2023, then jumped by 39.2% to $45.8 million in 2024, then grew by 16.52% to $53.4 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $53.4 million (Q3 2025), $45.8 million (Q3 2024), and $32.9 million (Q3 2023), per Business Quant data.